Will Big Pharma's next blockbuster be fish oil?

Some firms believe it's the upcoming, lucrative product in cardiology care.

By Benzinga Jun 28, 2013 5:11PM

You might take it now.

It’s marketed as being beneficial to patients with everything from depression issues to those who want a full head of hair, but drug companies like AstraZeneca (AZN), Amarin (AMRN) and GlaxoSmithKline (GSK) are betting on it for another reason.

Heart disease is the world’s largest killer. It accounts for 30% of deaths globally -- and while the thought of it sounds cold and uncaring, that makes for a huge market. Lipitor—at one time the world’s best-selling cholesterol-lowering drug, generated $13 billion annually for Pfizer (PFE) before going generic—and that’s only one drug.

That’s why companies are looking for the next lucrative product in the cardiology space. The newest bet is fish oil. Fish oil is believed to target triglycerides, small fatty substances in the blood that is linked to a higher heart attack risk.

Last month, AstraZeneca purchased fish-oil pill manufacturer, Omthera Pharmaceuticals for $443 million. At the time of the purchase CEO Pascal Soriot said, “There is a clear need for effective and convenient alternatives to some of the existing treatments.”

The problem isn’t so much alternatives as it is patent protection. Statin drugs are the standard for treating cholesterol problems, but the days of the blockbuster statin are behind the industry as the drugs go generic.

Omthera Pharmaceuticals makes Epanova -- a fish oil capsule only available by prescription. It’s a highly concentrated and purified product that AstraZeneca hopes to pair with its flagship statin, Crestor. Crestor goes off patent in 2016, making AstraZeneca search for new ways to market the drug.

But the problem with fish oil is the lack of evidence. Bloomberg points out that one Japanese study found that taking fish oil with a statin lowered heart attack risk by 19%. A late stage trial of a drug sponsored by Amarin found that it cut triglyceride levels by up to 22%.

But other studies, like one reported in the New England Journal of Medicine, found no positive effect. Another, published in the Journal of the American Medical Association in September, also found no effect on heart attack risk.

Scientists are skeptical along with the medical community, including Mark Urman, a practicing cardiologist. He said, “It’s very unclear what role fatty acids play for cardiac patients.” Big Pharma, however, plans to place a major bet on fish oil.

More from Benzinga
Jun 29, 2013 11:20AM
Run Nemo run....Swim as fast as you can, little one.
Jun 28, 2013 6:50PM
The fish certainly don't want to see this product approved!
Please help us to maintain a healthy and vibrant community by reporting any illegal or inappropriate behavior. If you believe a message violates theCode of Conductplease use this form to notify the moderators. They will investigate your report and take appropriate action. If necessary, they report all illegal activity to the proper authorities.
100 character limit
Are you sure you want to delete this comment?


Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

124 rated 1
266 rated 2
452 rated 3
702 rated 4
671 rated 5
604 rated 6
640 rated 7
495 rated 8
267 rated 9
158 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.